乳腺浸润性导管癌及其腋窝转移淋巴结中CCR5的表达变化及意义  

Changes and significance of chemokine receptor 5 in breast invasive ductal carcinoma and metastatic axillary nodes

作　　者：李文磊[1] 章阳[1] 孟凡云[2] 张伟[1] 姚玉民[1] 关众[1] 

机构地区：[1]聊城市人民医院,山东聊城252000 [2]聊城职业技术学院

出　　处：《山东医药》2009年第10期19-20,共2页Shandong Medical Journal

基　　金：山东省自然科学基金资助项目(Y2007C090)

摘　　要：目的探讨乳腺浸润性导管癌(IDC)及其腋窝转移淋巴结组织中趋化因子受体5(CCR5)的表达变化与腋窝淋巴结转移的关系。方法采用免疫组化法检测72例IDC组织及其腋窝淋巴结组织、50例乳腺纤维腺瘤组织中的CCR5。结果IDC组织CCR5阳性表达率为84.72%(61/72),乳腺纤维腺瘤组织为14%(7/50),两者相比,P<0.01;61例CCR5表达阳性的IDC中,腋窝淋巴结转移率为75.41%(46/61),与CCR5表达阴性者的36.36%(4/11)相比,P<0.05。50例伴有腋窝淋巴结转移的病例中,原发癌灶和淋巴结转移灶同时CCR5表达阳性者39例。结论CCR5在乳腺癌的发生、发展及腋窝淋巴结转移方面起作用,可作为预测乳腺癌腋窝淋巴结转移及预后的一个重要分子标志物。Objective To study the changes of chemokine receptor 5 （ CCR5 ） in breast cancer and metastatic axillary nodes. Methods CCR5 was detected by immunohistochemistry in 72 specimens of breast invasive ductal careinoma（IDC） and its corresponding axillary nodes, and 50 cases of fibroadenoma of breast. Results The positive expression rate of CCR5 in IDC was 84.72% （61/72）, which was higher than that in fibroadenoma of breast（ 14% ,P 〈 0.01 ）. The positive axillary node diversion rate in 61cases of CCR5 positive patients was 75.41%, which was higher than that of CCR5 nega- tive ones（ P 〈 0.05 ）. In 50 cases with axiUary node metastasis, there were 39 ones with positive expression of CCR5 in primary cancer and its corresponding axillary metastasis. Conclusions CCR5 plays a role in carcinogenesis, development and metastasis of breast cancer. CCR5 may be one of important tumor markets to predict axillary lymph node metastasis and prognosis of breast cancer.

关 键 词：乳腺肿瘤 趋化因子 趋化因子受体 肿瘤转移 

分 类 号：R737.9[医药卫生—肿瘤]